نتایج جستجو برای: peptide receptor radionuclide therapy

تعداد نتایج: 1363778  

2017
Aleksandra Marciniak Justyna Brasuń

Peptide receptor radionuclide therapy (PRRT) is a promising way to treat patients with inoperable tumors or metastatic neuroendocrine tumors. This therapeutic strategy is using radiolabeled peptides, which are capable of selective biding to receptors overexpressed in the cancer cells. One of the group of receptor-avid peptide used in the PRRT are the analogues of somatostatin (SST) connected to...

Journal: :Nuclear medicine review. Central & Eastern Europe 2011
Anna Sowa-Staszczak Dorota Pach Agnieszka Stefańska Monika Tomaszuk Wioletta Lenda-Tracz Renata Mikołajczak Dariusz Pawlak Robert Chrzan Aleksandra Gilis-Januszewska Elwira Przybylik-Mazurek Alicja Hubalewska-Dydejczyk

BACKGROUND The aim of the study was to assess the effectiveness of peptide receptor radionuclide therapy (PRRT) in patients with non-functioning neuroendocrine pancreatic tumours (NFPNTs) and to compare survival rates in patients with NFPNTs and in patients with other neuroendocrine tumours (NETs) treated using radiolabelled somatostatin analogue in our Department. We would like to analyze fact...

2018
Constantin Lapa Malte Kircher Heribert Hänscheid Andreas Schirbel Götz Ulrich Grigoleit Erdwine Klinker Markus Böck Samuel Samnick Theo Pelzer Andreas K Buck

Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positiv...

2014
Mark W Konijnenberg Wout A P Breeman Erik de Blois Ho Sze Chan Otto C Boerman Peter Laverman Petra Kolenc-Peitl Marleen Melis Marion de Jong

BACKGROUND Targeted radionuclide therapy with high-energy beta-emitters is generally considered suboptimal to cure small tumours (<300 mg). Tumour targeting of the CCK2 receptor-binding minigastrin analogue PP-F11 was determined in a tumour-bearing mouse model at increasing peptide amounts. The optimal therapy was analysed for PP-F11 labelled with (90)Y, (177)Lu or (213)Bi, accounting for the r...

Journal: :Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2007
Stephen J Mather Andrew J McKenzie Jane K Sosabowski Teresa M Morris David Ellison Susan A Watson

UNLABELLED The gastrin/cholecystokinin-2 (CCK-2) receptor has been identified as a possible target for peptide receptor radionuclide imaging and therapy. Several radiolabeled peptides binding to this receptor have been explored in animal models and clinical trials but either low tumor uptake or high renal retention has been found. The aim of this study was to identify a peptide with improved tu...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید